flavoxate

Trade name: urispas

Small moleculeapproved

Approved

Jan 15, 1970

Flavoxate is a drug, indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate is not indicated for definitive treatment, but is compatible with drugs used for the treatment of urinary tract infections. It was approved for use in the United States in 1970 and continues to be used. Drug acts as a direct antagonist at muscarinic acetylcholine receptors in cholinergically innervated organs. Its anticholinergic-parasympatholytic action reduces the tonus of smooth muscle in the bladder, effectively reducing the number of required voids, facilitating increased volume per void. Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety, restlessness and in some instances agitation and delusions. — NCATS

Clinical trial activity

2 trials · 3 clinical orgs · 5 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Sep 1, 2005 (NCT00440739)

Timeline

1970s

Jan 15, 1970
Johnson and Johnson — Earliest FDA Approval
Jan 15, 1970
Johnson and Johnson — NDA Secondary Org
Jan 15, 1970
Johnson and Johnson — NDA Organization

2000s

Aug 28, 2003
Impax Laboratories — Marketing Organization
Dec 16, 2004
Padagis Us — Marketing Organization
Dec 16, 2004
Paddock Laboratories — Marketing Organization
Nov 30, 2005
Epic Pharma Llc — Marketing Organization
Jan 1, 2009
Paddock Laboratories — Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

approvedJan 15, 1970

Chemistry & pharmacology

Loading structure…

SMILES

Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O

Mol. weight: 391.47 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Prescription Only

Oral

Yes

Parenteral

Topical

Sources

Also known as

2-(1-piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4h-chromene-8-carboxylate
2-(1-piperidinyl)ethyl 3-methyl-4-oxo-2-phenyl-4h-chromene-8-carboxylate
2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4h-1-benzopyran-8-carboxylate
2-piperidinoethyl 3-methyl-4-oxo-2-phenyl-4h-1-benzopyran-8-carboxylate
2-piperidinoethyl 3-methylflavone-8-carboxylate
2-piperidinoethyl 3-methylflavone-8-carboxylate
beta-piperidinoethyl 3-methylflavone-8-carboxylate
beta-piperidinoethyl 3-methylflavone-8-carboxylate
dw-61
dw-61
flavoxate
flavoxate
flavoxate
flavoxate
flavoxate
flavoxate
flavoxate
flavoxate
flavoxate hci
flavoxate hci
flavoxate hcl
flavoxate hcl
flavoxate hcl
flavoxate hydrochloride
flavoxate hydrochloride
flavoxate hydrochloride
flavoxate hydrochloride
flavoxato
flavoxato
flavoxatum
flavoxatum
urispas
urispas
urispas
urispas
urispas
urispas
urispas
urispas
urispas 200

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00992238	Phase 1	Oct 7, 2009	Paddock Laboratories, PRACS
NCT00440739	Phase 4	Sep 1, 2005	Mahidol University

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Mahidol University	Academic/Hospital	1	1	1	2005
Paddock Laboratories	For profit	1	1	1	2009
PRACS	For profit	1	0	1	2009

3 organizations

Page 1 / 1

Marketing (6)

Organization	Org type	Relationship	Date
Epic Pharma Llc	For profit	MKTG	Nov 30, 2005
Impax Laboratories	For profit	MKTG	Aug 28, 2003
Johnson and Johnson	For profit	NDA2	Jan 15, 1970
Johnson and Johnson	For profit	NDA	Jan 15, 1970
Padagis Us	For profit	MKTG	Dec 16, 2004
Paddock Laboratories	For profit	MKTG	Dec 16, 2004